Chemicals
Showing 32551–32700 of 41137 results
-
The polymyxins are cationic peptides originally isolated from B. polymyxa.{22080} They bind and kill Gram-negative bacteria.{22081} The B series of polymyxins consist of a cyclic heptapeptide and a tripeptide side chain acylated at the amino terminus by a fatty acid. Polymyxin B (sulfate) is a mixture of at least four closely related components, polymyxin B1 to B4, with polymyxin B1 (Item No. 14074) and B2 being the two major components.{22082,22304} Polymyxin B (sulfate) has rapid in vitro bactericidal activity against major multidrug-resistant Gram-negative bacteria, such as P. aeruginosa, A. baumannii, and K. pneumoniae.{22304}
Brand:CaymanSKU:- The polymyxins are cationic peptides originally isolated from B. polymyxa.{22080} They bind and kill Gram-negative bacteria.{22081} The B series of polymyxins consist of a cyclic heptapeptide and a tripeptide side chain acylated at the amino terminus by a fatty acid. Polymyxin B (sulfate) is a mixture of at least four closely related components, polymyxin B1 to B4, with polymyxin B1 (Item No. 14074) and B2 being the two major components.{22082,22304} Polymyxin B (sulfate) has rapid in vitro bactericidal activity against major multidrug-resistant Gram-negative bacteria, such as P. aeruginosa, A. baumannii, and K. pneumoniae.{22304}
Brand:CaymanSKU:-
The polymyxins are cationic peptides originally isolated from B. polymyxa.{22080} They bind and kill Gram-negative bacteria.{22081} The B series of polymyxins consist of a cyclic heptapeptide and a tripeptide side chain acylated at the amino terminus by a fatty acid. Polymyxin B1 Isoleucine differs from polymyxin B1 by having isoleucine rather than leucine as a component of the cyclic peptide. Polymyxin B1 isoleucine is comparable to other B polymyxins in its ability to kill P. aeruginosa, A. baumannii, and K. pneumoniae isolates.{22082} Its relative pharmacokinetics and nephrotoxicity have not been examined.
Brand:CaymanSKU:- The polymyxins are cationic peptides originally isolated from B. polymyxa.{22080} They bind and kill Gram-negative bacteria.{22081} The B series of polymyxins consist of a cyclic heptapeptide and a tripeptide side chain acylated at the amino terminus by a fatty acid. Polymyxin B1 Isoleucine differs from polymyxin B1 by having isoleucine rather than leucine as a component of the cyclic peptide. Polymyxin B1 isoleucine is comparable to other B polymyxins in its ability to kill P. aeruginosa, A. baumannii, and K. pneumoniae isolates.{22082} Its relative pharmacokinetics and nephrotoxicity have not been examined.
Brand:CaymanSKU:-
Polyphyllin I is a steroid saponin that has been found in P. polyphylla and has anticancer activity.{47762} It decreases proliferation of, and induces apoptosis in, MCF-7 and MDA-MB-231 cells (IC50s = 5 and 2.5 µM, respectively). It disrupts the mitochondrial membrane potential, activates caspase-3, and increases protein levels of the caspase-3 substrate poly(ADP-ribose) polymerase (PARP) in HepG2 and drug-resistant R-HepG2 cells.{47763} Polyphyllin I (2.05 and 2.73 mg/kg for 10 days) reduces tumor growth in an MCF-7 mouse xenograft model.{47762}
Brand:CaymanSKU:29179 - 10 mgAvailable on backorder
Polyphyllin I is a steroid saponin that has been found in P. polyphylla and has anticancer activity.{47762} It decreases proliferation of, and induces apoptosis in, MCF-7 and MDA-MB-231 cells (IC50s = 5 and 2.5 µM, respectively). It disrupts the mitochondrial membrane potential, activates caspase-3, and increases protein levels of the caspase-3 substrate poly(ADP-ribose) polymerase (PARP) in HepG2 and drug-resistant R-HepG2 cells.{47763} Polyphyllin I (2.05 and 2.73 mg/kg for 10 days) reduces tumor growth in an MCF-7 mouse xenograft model.{47762}
Brand:CaymanSKU:29179 - 25 mgAvailable on backorder
Polyphyllin I is a steroid saponin that has been found in P. polyphylla and has anticancer activity.{47762} It decreases proliferation of, and induces apoptosis in, MCF-7 and MDA-MB-231 cells (IC50s = 5 and 2.5 µM, respectively). It disrupts the mitochondrial membrane potential, activates caspase-3, and increases protein levels of the caspase-3 substrate poly(ADP-ribose) polymerase (PARP) in HepG2 and drug-resistant R-HepG2 cells.{47763} Polyphyllin I (2.05 and 2.73 mg/kg for 10 days) reduces tumor growth in an MCF-7 mouse xenograft model.{47762}
Brand:CaymanSKU:29179 - 5 mgAvailable on backorder
Polyphyllin I is a steroid saponin that has been found in P. polyphylla and has anticancer activity.{47762} It decreases proliferation of, and induces apoptosis in, MCF-7 and MDA-MB-231 cells (IC50s = 5 and 2.5 µM, respectively). It disrupts the mitochondrial membrane potential, activates caspase-3, and increases protein levels of the caspase-3 substrate poly(ADP-ribose) polymerase (PARP) in HepG2 and drug-resistant R-HepG2 cells.{47763} Polyphyllin I (2.05 and 2.73 mg/kg for 10 days) reduces tumor growth in an MCF-7 mouse xenograft model.{47762}
Brand:CaymanSKU:29179 - 50 mgAvailable on backorder
Brand:CaymanSKU:400035 - 1 eaAvailable on backorder
POM 1 is a polyoxometalate that inhibits ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) 1 and 3 with Ki values of 2.58 and 3.26 µM, respectively.{33011} It demonstrates 10-fold lower inhibitory activity for NTPDase 2 (Ki = 28.8 µM) and does not inhibit P2Y12 receptors (Ki > 10 µM).{33011} Inhibition of ecto-NTPDases that are capable of hydrolyzing nucleoside tri- and diphosphates (i.e., ATP, ADP, UTP, or UDP) can result in a potentiation of purinergic signaling due to an increase in the extracellular nucleotide concentrations. This subtype-selective NTPase inhibitor has been used to investigate the mechanisms of purinergic signaling.{33012}
Brand:CaymanSKU:21160 -Out of stock
POM 1 is a polyoxometalate that inhibits ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) 1 and 3 with Ki values of 2.58 and 3.26 µM, respectively.{33011} It demonstrates 10-fold lower inhibitory activity for NTPDase 2 (Ki = 28.8 µM) and does not inhibit P2Y12 receptors (Ki > 10 µM).{33011} Inhibition of ecto-NTPDases that are capable of hydrolyzing nucleoside tri- and diphosphates (i.e., ATP, ADP, UTP, or UDP) can result in a potentiation of purinergic signaling due to an increase in the extracellular nucleotide concentrations. This subtype-selective NTPase inhibitor has been used to investigate the mechanisms of purinergic signaling.{33012}
Brand:CaymanSKU:21160 -Out of stock
POM 1 is a polyoxometalate that inhibits ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) 1 and 3 with Ki values of 2.58 and 3.26 µM, respectively.{33011} It demonstrates 10-fold lower inhibitory activity for NTPDase 2 (Ki = 28.8 µM) and does not inhibit P2Y12 receptors (Ki > 10 µM).{33011} Inhibition of ecto-NTPDases that are capable of hydrolyzing nucleoside tri- and diphosphates (i.e., ATP, ADP, UTP, or UDP) can result in a potentiation of purinergic signaling due to an increase in the extracellular nucleotide concentrations. This subtype-selective NTPase inhibitor has been used to investigate the mechanisms of purinergic signaling.{33012}
Brand:CaymanSKU:21160 -Out of stock
Pomalidomide is an analog of thalidomide (Item No. 14610) that inhibits the E3 ligase protein cereblon (CRBN) with an IC50 value of approximately 3 µM for the human recombinant CRBN-DNA damage binding protein-1 (CRBN-DDB1) complex.{23504} It inhibits autoubiquitination of CRBN in HEK293T cells expressing CRBN but not those expressing a thalidomide-binding defective CRBN mutation. It inhibits proliferation of U266 myeloma cells when used at concentrations ranging from 0.1 to 10 µM. Pomalidomide also has antiangiogenic and immunomodulatory effects against myeloma cells, modulating cell adhesion, decreasing production of key pro-survival cytokines, including TNF-α, and triggering the activation of caspase-8.{23505,23398} Pomalidomide (3 mg/kg per day), in combination with dexamethasone, reduces tumor growth in a H929 R10-1 lenalidomide-resistant mouse xenograft model.{42256} Formulations containing pomalidomide have been used in the treatment of multiple myeloma.
Brand:CaymanSKU:19877 -Available on backorder
Pomalidomide is an analog of thalidomide (Item No. 14610) that inhibits the E3 ligase protein cereblon (CRBN) with an IC50 value of approximately 3 µM for the human recombinant CRBN-DNA damage binding protein-1 (CRBN-DDB1) complex.{23504} It inhibits autoubiquitination of CRBN in HEK293T cells expressing CRBN but not those expressing a thalidomide-binding defective CRBN mutation. It inhibits proliferation of U266 myeloma cells when used at concentrations ranging from 0.1 to 10 µM. Pomalidomide also has antiangiogenic and immunomodulatory effects against myeloma cells, modulating cell adhesion, decreasing production of key pro-survival cytokines, including TNF-α, and triggering the activation of caspase-8.{23505,23398} Pomalidomide (3 mg/kg per day), in combination with dexamethasone, reduces tumor growth in a H929 R10-1 lenalidomide-resistant mouse xenograft model.{42256} Formulations containing pomalidomide have been used in the treatment of multiple myeloma.
Brand:CaymanSKU:19877 -Available on backorder
Pomalidomide is an analog of thalidomide (Item No. 14610) that inhibits the E3 ligase protein cereblon (CRBN) with an IC50 value of approximately 3 µM for the human recombinant CRBN-DNA damage binding protein-1 (CRBN-DDB1) complex.{23504} It inhibits autoubiquitination of CRBN in HEK293T cells expressing CRBN but not those expressing a thalidomide-binding defective CRBN mutation. It inhibits proliferation of U266 myeloma cells when used at concentrations ranging from 0.1 to 10 µM. Pomalidomide also has antiangiogenic and immunomodulatory effects against myeloma cells, modulating cell adhesion, decreasing production of key pro-survival cytokines, including TNF-α, and triggering the activation of caspase-8.{23505,23398} Pomalidomide (3 mg/kg per day), in combination with dexamethasone, reduces tumor growth in a H929 R10-1 lenalidomide-resistant mouse xenograft model.{42256} Formulations containing pomalidomide have been used in the treatment of multiple myeloma.
Brand:CaymanSKU:19877 -Available on backorder
Pomalidomide is an analog of thalidomide (Item No. 14610) that inhibits the E3 ligase protein cereblon (CRBN) with an IC50 value of approximately 3 µM for the human recombinant CRBN-DNA damage binding protein-1 (CRBN-DDB1) complex.{23504} It inhibits autoubiquitination of CRBN in HEK293T cells expressing CRBN but not those expressing a thalidomide-binding defective CRBN mutation. It inhibits proliferation of U266 myeloma cells when used at concentrations ranging from 0.1 to 10 µM. Pomalidomide also has antiangiogenic and immunomodulatory effects against myeloma cells, modulating cell adhesion, decreasing production of key pro-survival cytokines, including TNF-α, and triggering the activation of caspase-8.{23505,23398} Pomalidomide (3 mg/kg per day), in combination with dexamethasone, reduces tumor growth in a H929 R10-1 lenalidomide-resistant mouse xenograft model.{42256} Formulations containing pomalidomide have been used in the treatment of multiple myeloma.
Brand:CaymanSKU:19877 -Available on backorder
Pomalidomide-d5 is intended for use as an internal standard for the quantification of pomalidomide (Item No. 19877) by GC- or LC-MS. Pomalidomide is an analog of thalidomide (Item No. 14610) that inhibits the E3 ligase protein cereblon (CRBN) with an IC50 value of approximately 3 µM for the human recombinant CRBN-DNA damage binding protein-1 (CRBN-DDB1) complex.{23504} It inhibits autoubiquitination of CRBN in HEK293T cells expressing CRBN but not those expressing a thalidomide-binding defective CRBN mutation. It inhibits proliferation of U266 myeloma cells when used at concentrations ranging from 0.1 to 10 µM. Pomalidomide also has antiangiogenic and immunomodulatory effects against myeloma cells, modulating cell adhesion, decreasing production of key pro-survival cytokines, including TNF-α, and triggering the activation of caspase-8.{23505,23398} Pomalidomide (3 mg/kg per day), in combination with dexamethasone, reduces tumor growth in a H929 R10-1 lenalidomide-resistant mouse xenograft model.{42256} Formulations containing pomalidomide have been used in the treatment of multiple myeloma.
Brand:CaymanSKU:25358 - 1 mgAvailable on backorder
Pomalidomide-d5 is intended for use as an internal standard for the quantification of pomalidomide (Item No. 19877) by GC- or LC-MS. Pomalidomide is an analog of thalidomide (Item No. 14610) that inhibits the E3 ligase protein cereblon (CRBN) with an IC50 value of approximately 3 µM for the human recombinant CRBN-DNA damage binding protein-1 (CRBN-DDB1) complex.{23504} It inhibits autoubiquitination of CRBN in HEK293T cells expressing CRBN but not those expressing a thalidomide-binding defective CRBN mutation. It inhibits proliferation of U266 myeloma cells when used at concentrations ranging from 0.1 to 10 µM. Pomalidomide also has antiangiogenic and immunomodulatory effects against myeloma cells, modulating cell adhesion, decreasing production of key pro-survival cytokines, including TNF-α, and triggering the activation of caspase-8.{23505,23398} Pomalidomide (3 mg/kg per day), in combination with dexamethasone, reduces tumor growth in a H929 R10-1 lenalidomide-resistant mouse xenograft model.{42256} Formulations containing pomalidomide have been used in the treatment of multiple myeloma.
Brand:CaymanSKU:25358 - 500 µgAvailable on backorder
Ponasterone A is an analog of 20-hydroxy ecdysone (Item No. 16145), the insect steroid hormone that regulates the metamorphosis of Drosophila.{26314} Ecdysteroids such as this compound have been employed as inducers of ecdysone-inducible mammalian expression systems.{26316,26315}
Brand:CaymanSKU:-Out of stock
Ponasterone A is an analog of 20-hydroxy ecdysone (Item No. 16145), the insect steroid hormone that regulates the metamorphosis of Drosophila.{26314} Ecdysteroids such as this compound have been employed as inducers of ecdysone-inducible mammalian expression systems.{26316,26315}
Brand:CaymanSKU:-Out of stock
Ponasterone A is an analog of 20-hydroxy ecdysone (Item No. 16145), the insect steroid hormone that regulates the metamorphosis of Drosophila.{26314} Ecdysteroids such as this compound have been employed as inducers of ecdysone-inducible mammalian expression systems.{26316,26315}
Brand:CaymanSKU:-Out of stock
Ponasterone A is an analog of 20-hydroxy ecdysone (Item No. 16145), the insect steroid hormone that regulates the metamorphosis of Drosophila.{26314} Ecdysteroids such as this compound have been employed as inducers of ecdysone-inducible mammalian expression systems.{26316,26315}
Brand:CaymanSKU:-Out of stock
Ponatinib is an orally bioavailable Bcr-Abl tyrosine kinase inhibitor (IC50 = 0.37 nM).{25003} It inhibits the tyrosine kinase inhibitor-resistant mutant Bcr-AblT315I (IC50 = 2 nM), as well as Bcr-AblQ252H, Bcr-AblY253F, Bcr-AblM351T, and Bcr-AblH396P mutants (IC50s = 0.44, 0.3, 0.3, and 0.34 nM, respectively). It is selective for Bcr-Abl and these mutants over the insulin receptor, IGF-1R, Aurora A kinase, and Cdk2/cyclin E but does inhibit the receptor tyrosine kinases c-Src, VEGF receptor 2 (VEGFR2), FGFR1, and PDGFRα (IC50s = 5.4, 1.5, 2.2, and 1.1 nM, respectively). Ponatinib inhibits proliferation of Ba/F3 cells expressing native (IC50 = 0.5 nM) or mutant Bcr-Abl (IC50s = 0.5-36 nM) and induces apoptosis. It reduces tumor growth in a Ba/F3 Bcr-AblT315I mouse xenograft model when administered at doses ranging from 10 to 30 mg/kg. Formulations containing ponatinib have been used in the treatment of chronic-, accelerated-, or blast-phase chronic myeloid leukemia (CML), T315I-positive CML, or T315I-positive Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
Brand:CaymanSKU:11494 - 1 mgAvailable on backorder
Ponatinib is an orally bioavailable Bcr-Abl tyrosine kinase inhibitor (IC50 = 0.37 nM).{25003} It inhibits the tyrosine kinase inhibitor-resistant mutant Bcr-AblT315I (IC50 = 2 nM), as well as Bcr-AblQ252H, Bcr-AblY253F, Bcr-AblM351T, and Bcr-AblH396P mutants (IC50s = 0.44, 0.3, 0.3, and 0.34 nM, respectively). It is selective for Bcr-Abl and these mutants over the insulin receptor, IGF-1R, Aurora A kinase, and Cdk2/cyclin E but does inhibit the receptor tyrosine kinases c-Src, VEGF receptor 2 (VEGFR2), FGFR1, and PDGFRα (IC50s = 5.4, 1.5, 2.2, and 1.1 nM, respectively). Ponatinib inhibits proliferation of Ba/F3 cells expressing native (IC50 = 0.5 nM) or mutant Bcr-Abl (IC50s = 0.5-36 nM) and induces apoptosis. It reduces tumor growth in a Ba/F3 Bcr-AblT315I mouse xenograft model when administered at doses ranging from 10 to 30 mg/kg. Formulations containing ponatinib have been used in the treatment of chronic-, accelerated-, or blast-phase chronic myeloid leukemia (CML), T315I-positive CML, or T315I-positive Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
Brand:CaymanSKU:11494 - 10 mgAvailable on backorder
Ponatinib is an orally bioavailable Bcr-Abl tyrosine kinase inhibitor (IC50 = 0.37 nM).{25003} It inhibits the tyrosine kinase inhibitor-resistant mutant Bcr-AblT315I (IC50 = 2 nM), as well as Bcr-AblQ252H, Bcr-AblY253F, Bcr-AblM351T, and Bcr-AblH396P mutants (IC50s = 0.44, 0.3, 0.3, and 0.34 nM, respectively). It is selective for Bcr-Abl and these mutants over the insulin receptor, IGF-1R, Aurora A kinase, and Cdk2/cyclin E but does inhibit the receptor tyrosine kinases c-Src, VEGF receptor 2 (VEGFR2), FGFR1, and PDGFRα (IC50s = 5.4, 1.5, 2.2, and 1.1 nM, respectively). Ponatinib inhibits proliferation of Ba/F3 cells expressing native (IC50 = 0.5 nM) or mutant Bcr-Abl (IC50s = 0.5-36 nM) and induces apoptosis. It reduces tumor growth in a Ba/F3 Bcr-AblT315I mouse xenograft model when administered at doses ranging from 10 to 30 mg/kg. Formulations containing ponatinib have been used in the treatment of chronic-, accelerated-, or blast-phase chronic myeloid leukemia (CML), T315I-positive CML, or T315I-positive Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
Brand:CaymanSKU:11494 - 5 mgAvailable on backorder
Ponatinib is an orally bioavailable Bcr-Abl tyrosine kinase inhibitor (IC50 = 0.37 nM).{25003} It inhibits the tyrosine kinase inhibitor-resistant mutant Bcr-AblT315I (IC50 = 2 nM), as well as Bcr-AblQ252H, Bcr-AblY253F, Bcr-AblM351T, and Bcr-AblH396P mutants (IC50s = 0.44, 0.3, 0.3, and 0.34 nM, respectively). It is selective for Bcr-Abl and these mutants over the insulin receptor, IGF-1R, Aurora A kinase, and Cdk2/cyclin E but does inhibit the receptor tyrosine kinases c-Src, VEGF receptor 2 (VEGFR2), FGFR1, and PDGFRα (IC50s = 5.4, 1.5, 2.2, and 1.1 nM, respectively). Ponatinib inhibits proliferation of Ba/F3 cells expressing native (IC50 = 0.5 nM) or mutant Bcr-Abl (IC50s = 0.5-36 nM) and induces apoptosis. It reduces tumor growth in a Ba/F3 Bcr-AblT315I mouse xenograft model when administered at doses ranging from 10 to 30 mg/kg. Formulations containing ponatinib have been used in the treatment of chronic-, accelerated-, or blast-phase chronic myeloid leukemia (CML), T315I-positive CML, or T315I-positive Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
Brand:CaymanSKU:11494 - 50 mgAvailable on backorder
Ponatinib-d8 is intended for use as an internal standard for the quantification of ponatinib (Item No. 11494) by GC- or LC-MS. Ponatinib is an orally bioavailable Bcr-Abl tyrosine kinase inhibitor (IC50 = 0.37 nM).{25003} It inhibits the tyrosine kinase inhibitor-resistant mutant Bcr-AblT315I (IC50 = 2 nM), as well as Bcr-AblQ252H, Bcr-AblY253F, Bcr-AblM351T, and Bcr-AblH396P mutants (IC50s = 0.44, 0.3, 0.3, and 0.34 nM, respectively). It is selective for Bcr-Abl and these mutants over the insulin receptor, IGF-1R, Aurora A kinase, and Cdk2/cyclin E but does inhibit the receptor tyrosine kinases c-Src, VEGF receptor 2 (VEGFR2), FGFR1, and PDGFRα (IC50s = 5.4, 1.5, 2.2, and 1.1 nM, respectively). Ponatinib inhibits proliferation of Ba/F3 cells expressing native (IC50 = 0.5 nM) or mutant Bcr-Abl (IC50s = 0.5-36 nM) and induces apoptosis. It reduces tumor growth in a Ba/F3 Bcr-AblT315I mouse xenograft model when administered at doses ranging from 10 to 30 mg/kg. Formulations containing ponatinib have been used in the treatment of chronic-, accelerated-, or blast-phase chronic myeloid leukemia (CML), T315I-positive CML, or T315I-positive Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
Brand:CaymanSKU:28905 - 1 mgAvailable on backorder
Ponceau S is a stain that permits the rapid, reversible detection of proteins immobilized on various matrices, including nitrocellulose and polyvinylidene fluoride membranes.{22808} It can be used to locate proteins or evaluate efficiency of transfer. Reversible staining with ponceau S has also been validated as an alternative to actin probing as a loading control.{22807} This stain can also be used as a fiducial marker in mass spectrometric imaging.{22805}
Brand:CaymanSKU:- Ponceau S is a stain that permits the rapid, reversible detection of proteins immobilized on various matrices, including nitrocellulose and polyvinylidene fluoride membranes.{22808} It can be used to locate proteins or evaluate efficiency of transfer. Reversible staining with ponceau S has also been validated as an alternative to actin probing as a loading control.{22807} This stain can also be used as a fiducial marker in mass spectrometric imaging.{22805}
Brand:CaymanSKU:- Ponceau S is a stain that permits the rapid, reversible detection of proteins immobilized on various matrices, including nitrocellulose and polyvinylidene fluoride membranes.{22808} It can be used to locate proteins or evaluate efficiency of transfer. Reversible staining with ponceau S has also been validated as an alternative to actin probing as a loading control.{22807} This stain can also be used as a fiducial marker in mass spectrometric imaging.{22805}
Brand:CaymanSKU:-
Poncirin is a flavonoid glycoside that has been found in P. trifoliata and has diverse biological activities.{60090,60091,60092,60103} It inhibits the growth of SGC-7901 gastric cancer cells when used at concentrations ranging from 5 to 25 µg/ml.{60091} Poncirin (25-100 µM) inhibits LPS-induced NF-κB DNA-binding activity, as well as production of nitric oxide (NO) and prostaglandin E2 (PGE2; Item No. 14010) in RAW 264.7 cells.{60092} It reduces the gastric ulcer lesion index in a rat model of HCl/ethanol-induced gastritis when administered at doses of 50 and 100 mg/kg.{60103}
Brand:CaymanSKU:31706 - 1 mgAvailable on backorder
Poncirin is a flavonoid glycoside that has been found in P. trifoliata and has diverse biological activities.{60090,60091,60092,60103} It inhibits the growth of SGC-7901 gastric cancer cells when used at concentrations ranging from 5 to 25 µg/ml.{60091} Poncirin (25-100 µM) inhibits LPS-induced NF-κB DNA-binding activity, as well as production of nitric oxide (NO) and prostaglandin E2 (PGE2; Item No. 14010) in RAW 264.7 cells.{60092} It reduces the gastric ulcer lesion index in a rat model of HCl/ethanol-induced gastritis when administered at doses of 50 and 100 mg/kg.{60103}
Brand:CaymanSKU:31706 - 10 mgAvailable on backorder
Poncirin is a flavonoid glycoside that has been found in P. trifoliata and has diverse biological activities.{60090,60091,60092,60103} It inhibits the growth of SGC-7901 gastric cancer cells when used at concentrations ranging from 5 to 25 µg/ml.{60091} Poncirin (25-100 µM) inhibits LPS-induced NF-κB DNA-binding activity, as well as production of nitric oxide (NO) and prostaglandin E2 (PGE2; Item No. 14010) in RAW 264.7 cells.{60092} It reduces the gastric ulcer lesion index in a rat model of HCl/ethanol-induced gastritis when administered at doses of 50 and 100 mg/kg.{60103}
Brand:CaymanSKU:31706 - 5 mgAvailable on backorder
Ponesimod is a potent agonist of sphingosine-1-phosphate receptor 1 (S1P1/EDG-1; IC50s = 6, >10,000, 2,068, 1,956, and 142 nM for S1P1-S1P5, respectively, in a radioligand binding assay).{38368} It selectively activates S1P1 in a GTPγS assay (EC50s = 5.7, >10,000, 105, 1,108, and 59.1 nM, for S1P1-S1P5, respectively). Ponesimod (3-100 mg/kg) reduces the number of circulating lymphocytes in rats in a dose-dependent manner. It reduces edema, protein extravasation, neutrophil activity, and skin levels of the proinflammatory cytokines IL-1β, IL-6, IFN-γ, and TNF-α in a mouse model of delayed-type hypersensitivity at a dose of 30 mg/kg.{38369} Ponesimod (30 mg/kg) also prevents footpad swelling in a rat model of adjuvant-induced arthritis.
Brand:CaymanSKU:22053 -Out of stock
Ponesimod is a potent agonist of sphingosine-1-phosphate receptor 1 (S1P1/EDG-1; IC50s = 6, >10,000, 2,068, 1,956, and 142 nM for S1P1-S1P5, respectively, in a radioligand binding assay).{38368} It selectively activates S1P1 in a GTPγS assay (EC50s = 5.7, >10,000, 105, 1,108, and 59.1 nM, for S1P1-S1P5, respectively). Ponesimod (3-100 mg/kg) reduces the number of circulating lymphocytes in rats in a dose-dependent manner. It reduces edema, protein extravasation, neutrophil activity, and skin levels of the proinflammatory cytokines IL-1β, IL-6, IFN-γ, and TNF-α in a mouse model of delayed-type hypersensitivity at a dose of 30 mg/kg.{38369} Ponesimod (30 mg/kg) also prevents footpad swelling in a rat model of adjuvant-induced arthritis.
Brand:CaymanSKU:22053 -Out of stock
Ponesimod is a potent agonist of sphingosine-1-phosphate receptor 1 (S1P1/EDG-1; IC50s = 6, >10,000, 2,068, 1,956, and 142 nM for S1P1-S1P5, respectively, in a radioligand binding assay).{38368} It selectively activates S1P1 in a GTPγS assay (EC50s = 5.7, >10,000, 105, 1,108, and 59.1 nM, for S1P1-S1P5, respectively). Ponesimod (3-100 mg/kg) reduces the number of circulating lymphocytes in rats in a dose-dependent manner. It reduces edema, protein extravasation, neutrophil activity, and skin levels of the proinflammatory cytokines IL-1β, IL-6, IFN-γ, and TNF-α in a mouse model of delayed-type hypersensitivity at a dose of 30 mg/kg.{38369} Ponesimod (30 mg/kg) also prevents footpad swelling in a rat model of adjuvant-induced arthritis.
Brand:CaymanSKU:22053 -Out of stock
Ponesimod is a potent agonist of sphingosine-1-phosphate receptor 1 (S1P1/EDG-1; IC50s = 6, >10,000, 2,068, 1,956, and 142 nM for S1P1-S1P5, respectively, in a radioligand binding assay).{38368} It selectively activates S1P1 in a GTPγS assay (EC50s = 5.7, >10,000, 105, 1,108, and 59.1 nM, for S1P1-S1P5, respectively). Ponesimod (3-100 mg/kg) reduces the number of circulating lymphocytes in rats in a dose-dependent manner. It reduces edema, protein extravasation, neutrophil activity, and skin levels of the proinflammatory cytokines IL-1β, IL-6, IFN-γ, and TNF-α in a mouse model of delayed-type hypersensitivity at a dose of 30 mg/kg.{38369} Ponesimod (30 mg/kg) also prevents footpad swelling in a rat model of adjuvant-induced arthritis.
Brand:CaymanSKU:22053 -Out of stock
Porcupine-IN-1 is an inhibitor of the Wnt and hedgehog signaling pathways (IC50s = 0.5 and 71 nM, respectively, in cell-based reporter assays).{47087,47088} It inhibits secretion of Wnt3A from Wnt3A-transfected HEK293T cells when used at a concentration of 0.1 μM, indicating inhibition of porcupine, an enzyme that catalyzes palmitoylation of Wnt proteins.{47087}
Brand:CaymanSKU:25834 - 1 mgAvailable on backorder
Porcupine-IN-1 is an inhibitor of the Wnt and hedgehog signaling pathways (IC50s = 0.5 and 71 nM, respectively, in cell-based reporter assays).{47087,47088} It inhibits secretion of Wnt3A from Wnt3A-transfected HEK293T cells when used at a concentration of 0.1 μM, indicating inhibition of porcupine, an enzyme that catalyzes palmitoylation of Wnt proteins.{47087}
Brand:CaymanSKU:25834 - 10 mgAvailable on backorder
Porcupine-IN-1 is an inhibitor of the Wnt and hedgehog signaling pathways (IC50s = 0.5 and 71 nM, respectively, in cell-based reporter assays).{47087,47088} It inhibits secretion of Wnt3A from Wnt3A-transfected HEK293T cells when used at a concentration of 0.1 μM, indicating inhibition of porcupine, an enzyme that catalyzes palmitoylation of Wnt proteins.{47087}
Brand:CaymanSKU:25834 - 25 mgAvailable on backorder
Porcupine-IN-1 is an inhibitor of the Wnt and hedgehog signaling pathways (IC50s = 0.5 and 71 nM, respectively, in cell-based reporter assays).{47087,47088} It inhibits secretion of Wnt3A from Wnt3A-transfected HEK293T cells when used at a concentration of 0.1 μM, indicating inhibition of porcupine, an enzyme that catalyzes palmitoylation of Wnt proteins.{47087}
Brand:CaymanSKU:25834 - 5 mgAvailable on backorder
Posaconazole is a broad-spectrum triazole active against various yeasts and molds, including Aspergillus, Candida, Fusarium, and Zygomycetes.{20805} Posaconazole inhibits the growth of fungi by inhibiting the lanosterol 14α-demethylase enzyme (IC50s range from 7-200 nM), which results in a disruption the synthesis of ergosterol (Item No. 19850), a key sterol necessary for fungal cell membrane integrity and for the function of certain membrane-bound proteins.{24400}
Brand:CaymanSKU:- Posaconazole is a broad-spectrum triazole active against various yeasts and molds, including Aspergillus, Candida, Fusarium, and Zygomycetes.{20805} Posaconazole inhibits the growth of fungi by inhibiting the lanosterol 14α-demethylase enzyme (IC50s range from 7-200 nM), which results in a disruption the synthesis of ergosterol (Item No. 19850), a key sterol necessary for fungal cell membrane integrity and for the function of certain membrane-bound proteins.{24400}
Brand:CaymanSKU:- Posaconazole is a broad-spectrum triazole active against various yeasts and molds, including Aspergillus, Candida, Fusarium, and Zygomycetes.{20805} Posaconazole inhibits the growth of fungi by inhibiting the lanosterol 14α-demethylase enzyme (IC50s range from 7-200 nM), which results in a disruption the synthesis of ergosterol (Item No. 19850), a key sterol necessary for fungal cell membrane integrity and for the function of certain membrane-bound proteins.{24400}
Brand:CaymanSKU:- Brand:CaymanSKU:400029 - 1 eaAvailable on backorder
Brand:CaymanSKU:400029 - 5 eaAvailable on backorder
Oxidized low-density lipoprotien (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic.{9800} Many of these substances were recently isolated and purified from oxLDL, and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position.{9891} 1-(Palmitoyl)-2-(5-oxovaleroyl)-phosphatidylcholine, or POV-PC, is one of the oxLDL species derived from 2-arachidonoyl or eicosapentanoyl phospholipids.{9890} POV-PC confers CD36 scavenger receptor binding affinity more potently than any hydroperoxy PC species, and may be one of the more important structural determinants of oxLDL. Treatment of cultured endothelial cells with POV-PC stimulates monocyte binding, stimulates intracellular cAMP production, and strongly inhibits the LPS-induced binding of neutrophils.{10396}
Brand:CaymanSKU:10031 - 1 mgAvailable on backorder
Oxidized low-density lipoprotien (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic.{9800} Many of these substances were recently isolated and purified from oxLDL, and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position.{9891} 1-(Palmitoyl)-2-(5-oxovaleroyl)-phosphatidylcholine, or POV-PC, is one of the oxLDL species derived from 2-arachidonoyl or eicosapentanoyl phospholipids.{9890} POV-PC confers CD36 scavenger receptor binding affinity more potently than any hydroperoxy PC species, and may be one of the more important structural determinants of oxLDL. Treatment of cultured endothelial cells with POV-PC stimulates monocyte binding, stimulates intracellular cAMP production, and strongly inhibits the LPS-induced binding of neutrophils.{10396}
Brand:CaymanSKU:10031 - 10 mgAvailable on backorder
Oxidized low-density lipoprotien (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic.{9800} Many of these substances were recently isolated and purified from oxLDL, and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position.{9891} 1-(Palmitoyl)-2-(5-oxovaleroyl)-phosphatidylcholine, or POV-PC, is one of the oxLDL species derived from 2-arachidonoyl or eicosapentanoyl phospholipids.{9890} POV-PC confers CD36 scavenger receptor binding affinity more potently than any hydroperoxy PC species, and may be one of the more important structural determinants of oxLDL. Treatment of cultured endothelial cells with POV-PC stimulates monocyte binding, stimulates intracellular cAMP production, and strongly inhibits the LPS-induced binding of neutrophils.{10396}
Brand:CaymanSKU:10031 - 25 mgAvailable on backorder
Oxidized low-density lipoprotien (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic.{9800} Many of these substances were recently isolated and purified from oxLDL, and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position.{9891} 1-(Palmitoyl)-2-(5-oxovaleroyl)-phosphatidylcholine, or POV-PC, is one of the oxLDL species derived from 2-arachidonoyl or eicosapentanoyl phospholipids.{9890} POV-PC confers CD36 scavenger receptor binding affinity more potently than any hydroperoxy PC species, and may be one of the more important structural determinants of oxLDL. Treatment of cultured endothelial cells with POV-PC stimulates monocyte binding, stimulates intracellular cAMP production, and strongly inhibits the LPS-induced binding of neutrophils.{10396}
Brand:CaymanSKU:10031 - 5 mgAvailable on backorder
Povidone-iodine is a microcide with broad-spectrum activity against bacteria, fungi, viruses, and protozoans.{48293} It reduces total anaerobic and aerobic bacterial counts in vitro in dog feces when applied topically as a 10% solution.{48294} Povidone-iodine decreases bacterial counts and the occurrence of anastomotic leaks in a dog model of emergent resection and anastomosis of the sigmoid colon when applied in situ at a concentration of 10% v/v. Topical administration of povidone-iodine (10% v/v) also reduces bacterial counts on the skin of cynomolgus monkeys.{48295} Formulations containing povidone-iodine have been used to disinfect skin before and after surgery.
Brand:CaymanSKU:27883 - 25 gAvailable on backorder
Povidone-iodine is a microcide with broad-spectrum activity against bacteria, fungi, viruses, and protozoans.{48293} It reduces total anaerobic and aerobic bacterial counts in vitro in dog feces when applied topically as a 10% solution.{48294} Povidone-iodine decreases bacterial counts and the occurrence of anastomotic leaks in a dog model of emergent resection and anastomosis of the sigmoid colon when applied in situ at a concentration of 10% v/v. Topical administration of povidone-iodine (10% v/v) also reduces bacterial counts on the skin of cynomolgus monkeys.{48295} Formulations containing povidone-iodine have been used to disinfect skin before and after surgery.
Brand:CaymanSKU:27883 - 50 gAvailable on backorder
Poziotinib is a potent inhibitor of EGFR family kinases with IC50 values of 3.2, 5.3, 23.5, 4.2, and 2.2 nM for wild-type EGFR, HER2, HER4, EGFRT790M, and EGFRL858R/T790M, respectively.{38157} It has greater than 100- to 1,000-fold selectivity for EGFR kinases over 30 other tested kinases in vitro. Poziotinib inhibits growth of wild-type and mutant EGFR kinase-dependent lung, breast, and gastric cancer cell lines (GI50s = 0.6-5.7 nM) and inhibits EGFR phosphorylation and induces apoptosis in vitro. In vivo, poziotinib reduces tumor size in an HCC827 non-small cell lung cancer mouse xenograft model. Formulations containing poziotinib are under investigation in clinical trials for the treatment of EGFR-mutant lung adenocarcinoma.{38158}
Brand:CaymanSKU:22437 -Out of stock
Poziotinib is a potent inhibitor of EGFR family kinases with IC50 values of 3.2, 5.3, 23.5, 4.2, and 2.2 nM for wild-type EGFR, HER2, HER4, EGFRT790M, and EGFRL858R/T790M, respectively.{38157} It has greater than 100- to 1,000-fold selectivity for EGFR kinases over 30 other tested kinases in vitro. Poziotinib inhibits growth of wild-type and mutant EGFR kinase-dependent lung, breast, and gastric cancer cell lines (GI50s = 0.6-5.7 nM) and inhibits EGFR phosphorylation and induces apoptosis in vitro. In vivo, poziotinib reduces tumor size in an HCC827 non-small cell lung cancer mouse xenograft model. Formulations containing poziotinib are under investigation in clinical trials for the treatment of EGFR-mutant lung adenocarcinoma.{38158}
Brand:CaymanSKU:22437 -Out of stock
Poziotinib is a potent inhibitor of EGFR family kinases with IC50 values of 3.2, 5.3, 23.5, 4.2, and 2.2 nM for wild-type EGFR, HER2, HER4, EGFRT790M, and EGFRL858R/T790M, respectively.{38157} It has greater than 100- to 1,000-fold selectivity for EGFR kinases over 30 other tested kinases in vitro. Poziotinib inhibits growth of wild-type and mutant EGFR kinase-dependent lung, breast, and gastric cancer cell lines (GI50s = 0.6-5.7 nM) and inhibits EGFR phosphorylation and induces apoptosis in vitro. In vivo, poziotinib reduces tumor size in an HCC827 non-small cell lung cancer mouse xenograft model. Formulations containing poziotinib are under investigation in clinical trials for the treatment of EGFR-mutant lung adenocarcinoma.{38158}
Brand:CaymanSKU:22437 -Out of stock
Poziotinib is a potent inhibitor of EGFR family kinases with IC50 values of 3.2, 5.3, 23.5, 4.2, and 2.2 nM for wild-type EGFR, HER2, HER4, EGFRT790M, and EGFRL858R/T790M, respectively.{38157} It has greater than 100- to 1,000-fold selectivity for EGFR kinases over 30 other tested kinases in vitro. Poziotinib inhibits growth of wild-type and mutant EGFR kinase-dependent lung, breast, and gastric cancer cell lines (GI50s = 0.6-5.7 nM) and inhibits EGFR phosphorylation and induces apoptosis in vitro. In vivo, poziotinib reduces tumor size in an HCC827 non-small cell lung cancer mouse xenograft model. Formulations containing poziotinib are under investigation in clinical trials for the treatment of EGFR-mutant lung adenocarcinoma.{38158}
Brand:CaymanSKU:22437 -Out of stock
PP1 is a potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases. It inhibits p56lck (IC50 = 5 nM), p59fynT (IC50 = 6 nM), Hck (IC50 = 20 nM), and Src (IC50 = 170 nM) without significantly affecting the activity of EGFR kinase (IC50 = 250 nM), JAK2 (IC50 = 50 µM), or ZAP-70 (IC50 ≥ 0.6 µM).{18539} PP1 inhibits anti-CD3-induced tyrosine phosphorylation of human T cells with an IC50 value of 600 nM.{18539} It exhibits antitumor activity by antagonizing both proliferation and the inhibition of apoptosis mediated by a stem cell factor/mast cell growth factor in hematopoietic and small cell lung cancer cell lines.{22348,22349} PP1 also blocks TGF-β-mediated cellular responses by directly inhibiting type I TGF-β receptors (IC50 = 50 nM) in a manner unrelated to Src signaling.{22347}
Brand:CaymanSKU:- PP1 is a potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases. It inhibits p56lck (IC50 = 5 nM), p59fynT (IC50 = 6 nM), Hck (IC50 = 20 nM), and Src (IC50 = 170 nM) without significantly affecting the activity of EGFR kinase (IC50 = 250 nM), JAK2 (IC50 = 50 µM), or ZAP-70 (IC50 ≥ 0.6 µM).{18539} PP1 inhibits anti-CD3-induced tyrosine phosphorylation of human T cells with an IC50 value of 600 nM.{18539} It exhibits antitumor activity by antagonizing both proliferation and the inhibition of apoptosis mediated by a stem cell factor/mast cell growth factor in hematopoietic and small cell lung cancer cell lines.{22348,22349} PP1 also blocks TGF-β-mediated cellular responses by directly inhibiting type I TGF-β receptors (IC50 = 50 nM) in a manner unrelated to Src signaling.{22347}
Brand:CaymanSKU:- PP1 is a potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases. It inhibits p56lck (IC50 = 5 nM), p59fynT (IC50 = 6 nM), Hck (IC50 = 20 nM), and Src (IC50 = 170 nM) without significantly affecting the activity of EGFR kinase (IC50 = 250 nM), JAK2 (IC50 = 50 µM), or ZAP-70 (IC50 ≥ 0.6 µM).{18539} PP1 inhibits anti-CD3-induced tyrosine phosphorylation of human T cells with an IC50 value of 600 nM.{18539} It exhibits antitumor activity by antagonizing both proliferation and the inhibition of apoptosis mediated by a stem cell factor/mast cell growth factor in hematopoietic and small cell lung cancer cell lines.{22348,22349} PP1 also blocks TGF-β-mediated cellular responses by directly inhibiting type I TGF-β receptors (IC50 = 50 nM) in a manner unrelated to Src signaling.{22347}
Brand:CaymanSKU:- PP1 is a potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases. It inhibits p56lck (IC50 = 5 nM), p59fynT (IC50 = 6 nM), Hck (IC50 = 20 nM), and Src (IC50 = 170 nM) without significantly affecting the activity of EGFR kinase (IC50 = 250 nM), JAK2 (IC50 = 50 µM), or ZAP-70 (IC50 ≥ 0.6 µM).{18539} PP1 inhibits anti-CD3-induced tyrosine phosphorylation of human T cells with an IC50 value of 600 nM.{18539} It exhibits antitumor activity by antagonizing both proliferation and the inhibition of apoptosis mediated by a stem cell factor/mast cell growth factor in hematopoietic and small cell lung cancer cell lines.{22348,22349} PP1 also blocks TGF-β-mediated cellular responses by directly inhibiting type I TGF-β receptors (IC50 = 50 nM) in a manner unrelated to Src signaling.{22347}
Brand:CaymanSKU:-
PP121 is a potent dual inhibitor of tyrosine and phosphoinositide kinases with IC50 values ranging from 2 to 60 nM for p110α, mTOR, Src, Abl, and VEGFR.{17883} It demonstrates >90% inhibition of tyrosine kinases and 50 = 50 nM) in vitro. It blocks VEGF-driven human umbilical vein endothelial cell (HUVEC) tube formation (IC50 = 0.31 nM), an in vitro model of tumor angiogenesis. PP121 also inhibits MEKK2/MAP3K2 (IC50 = 31 nM), a kinase important for tumor growth and metastasis.{38183}
Brand:CaymanSKU:21196 -Out of stock
PP121 is a potent dual inhibitor of tyrosine and phosphoinositide kinases with IC50 values ranging from 2 to 60 nM for p110α, mTOR, Src, Abl, and VEGFR.{17883} It demonstrates >90% inhibition of tyrosine kinases and 50 = 50 nM) in vitro. It blocks VEGF-driven human umbilical vein endothelial cell (HUVEC) tube formation (IC50 = 0.31 nM), an in vitro model of tumor angiogenesis. PP121 also inhibits MEKK2/MAP3K2 (IC50 = 31 nM), a kinase important for tumor growth and metastasis.{38183}
Brand:CaymanSKU:21196 -Out of stock
PP121 is a potent dual inhibitor of tyrosine and phosphoinositide kinases with IC50 values ranging from 2 to 60 nM for p110α, mTOR, Src, Abl, and VEGFR.{17883} It demonstrates >90% inhibition of tyrosine kinases and 50 = 50 nM) in vitro. It blocks VEGF-driven human umbilical vein endothelial cell (HUVEC) tube formation (IC50 = 0.31 nM), an in vitro model of tumor angiogenesis. PP121 also inhibits MEKK2/MAP3K2 (IC50 = 31 nM), a kinase important for tumor growth and metastasis.{38183}
Brand:CaymanSKU:21196 -Out of stock
PP121 is a potent dual inhibitor of tyrosine and phosphoinositide kinases with IC50 values ranging from 2 to 60 nM for p110α, mTOR, Src, Abl, and VEGFR.{17883} It demonstrates >90% inhibition of tyrosine kinases and 50 = 50 nM) in vitro. It blocks VEGF-driven human umbilical vein endothelial cell (HUVEC) tube formation (IC50 = 0.31 nM), an in vitro model of tumor angiogenesis. PP121 also inhibits MEKK2/MAP3K2 (IC50 = 31 nM), a kinase important for tumor growth and metastasis.{38183}
Brand:CaymanSKU:21196 -Out of stock
The Src family of non-receptor tyrosine kinases regulate cell adhesion, growth, and differentiation through activation of multiple intracellular signaling pathways. Normally inactive, Src kinases are transiently activated during mitosis and constitutively activated by abnormal mutations. PP2 is a potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases. It inhibits p56lck (IC50 = 4 nM), p59fynT (IC50 = 5 nM), Hck (IC50 = 5 nM), and Src (IC50 = 100 nM).{18539} PP2 does not significantly affect the activity of EGFR kinase (IC50 = 480 nM), JAK2 (IC50 > 50 µM), or ZAP-70 (IC50 > 100 µM).{18539} PP2 inhibits the activation of focal adhesion kinase as well as its phosphorylation at Tyr577. PP2 also inhibits anti-CD3-stimulated tyrosine phosphorylation of human T-cells with an IC50 value of 600 nM.{18539}
Brand:CaymanSKU:- The Src family of non-receptor tyrosine kinases regulate cell adhesion, growth, and differentiation through activation of multiple intracellular signaling pathways. Normally inactive, Src kinases are transiently activated during mitosis and constitutively activated by abnormal mutations. PP2 is a potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases. It inhibits p56lck (IC50 = 4 nM), p59fynT (IC50 = 5 nM), Hck (IC50 = 5 nM), and Src (IC50 = 100 nM).{18539} PP2 does not significantly affect the activity of EGFR kinase (IC50 = 480 nM), JAK2 (IC50 > 50 µM), or ZAP-70 (IC50 > 100 µM).{18539} PP2 inhibits the activation of focal adhesion kinase as well as its phosphorylation at Tyr577. PP2 also inhibits anti-CD3-stimulated tyrosine phosphorylation of human T-cells with an IC50 value of 600 nM.{18539}
Brand:CaymanSKU:- The Src family of non-receptor tyrosine kinases regulate cell adhesion, growth, and differentiation through activation of multiple intracellular signaling pathways. Normally inactive, Src kinases are transiently activated during mitosis and constitutively activated by abnormal mutations. PP2 is a potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases. It inhibits p56lck (IC50 = 4 nM), p59fynT (IC50 = 5 nM), Hck (IC50 = 5 nM), and Src (IC50 = 100 nM).{18539} PP2 does not significantly affect the activity of EGFR kinase (IC50 = 480 nM), JAK2 (IC50 > 50 µM), or ZAP-70 (IC50 > 100 µM).{18539} PP2 inhibits the activation of focal adhesion kinase as well as its phosphorylation at Tyr577. PP2 also inhibits anti-CD3-stimulated tyrosine phosphorylation of human T-cells with an IC50 value of 600 nM.{18539}
Brand:CaymanSKU:- The Src family of non-receptor tyrosine kinases regulate cell adhesion, growth, and differentiation through activation of multiple intracellular signaling pathways. Normally inactive, Src kinases are transiently activated during mitosis and constitutively activated by abnormal mutations. PP2 is a potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases. It inhibits p56lck (IC50 = 4 nM), p59fynT (IC50 = 5 nM), Hck (IC50 = 5 nM), and Src (IC50 = 100 nM).{18539} PP2 does not significantly affect the activity of EGFR kinase (IC50 = 480 nM), JAK2 (IC50 > 50 µM), or ZAP-70 (IC50 > 100 µM).{18539} PP2 inhibits the activation of focal adhesion kinase as well as its phosphorylation at Tyr577. PP2 also inhibits anti-CD3-stimulated tyrosine phosphorylation of human T-cells with an IC50 value of 600 nM.{18539}
Brand:CaymanSKU:-
The mammalian target of rapamycin (mTOR) is a serine-threonine kinase that is central to two protein complexes, mTORC1 and mTORC2. These complexes are differentially regulated (e.g., only mTORC1 is sensitive to rapamycin) and regulate different pathways. PP242 is an inhibitor of the active site of mTOR kinase in both mTORC1 and mTORC2 (IC50 = 8 nM).{17883,19367} It less effectively inhibits PKCα, PI3-kinase subunit p110γ, JAK2, PKCβI, and PKCβII (IC50 = 49, 102, 110, 198, and 185, respectively).{19367,19883} PP242 has been shown to cause the death of certain human and murine leukemia cells more potently than rapamycin and, in vivo, delays leukemia onset and augments the effects of tyrosine kinase inhibitors in suppressing leukemic expansion and extending survival.{18005}
Brand:CaymanSKU:- The mammalian target of rapamycin (mTOR) is a serine-threonine kinase that is central to two protein complexes, mTORC1 and mTORC2. These complexes are differentially regulated (e.g., only mTORC1 is sensitive to rapamycin) and regulate different pathways. PP242 is an inhibitor of the active site of mTOR kinase in both mTORC1 and mTORC2 (IC50 = 8 nM).{17883,19367} It less effectively inhibits PKCα, PI3-kinase subunit p110γ, JAK2, PKCβI, and PKCβII (IC50 = 49, 102, 110, 198, and 185, respectively).{19367,19883} PP242 has been shown to cause the death of certain human and murine leukemia cells more potently than rapamycin and, in vivo, delays leukemia onset and augments the effects of tyrosine kinase inhibitors in suppressing leukemic expansion and extending survival.{18005}
Brand:CaymanSKU:- The mammalian target of rapamycin (mTOR) is a serine-threonine kinase that is central to two protein complexes, mTORC1 and mTORC2. These complexes are differentially regulated (e.g., only mTORC1 is sensitive to rapamycin) and regulate different pathways. PP242 is an inhibitor of the active site of mTOR kinase in both mTORC1 and mTORC2 (IC50 = 8 nM).{17883,19367} It less effectively inhibits PKCα, PI3-kinase subunit p110γ, JAK2, PKCβI, and PKCβII (IC50 = 49, 102, 110, 198, and 185, respectively).{19367,19883} PP242 has been shown to cause the death of certain human and murine leukemia cells more potently than rapamycin and, in vivo, delays leukemia onset and augments the effects of tyrosine kinase inhibitors in suppressing leukemic expansion and extending survival.{18005}
Brand:CaymanSKU:- The mammalian target of rapamycin (mTOR) is a serine-threonine kinase that is central to two protein complexes, mTORC1 and mTORC2. These complexes are differentially regulated (e.g., only mTORC1 is sensitive to rapamycin) and regulate different pathways. PP242 is an inhibitor of the active site of mTOR kinase in both mTORC1 and mTORC2 (IC50 = 8 nM).{17883,19367} It less effectively inhibits PKCα, PI3-kinase subunit p110γ, JAK2, PKCβI, and PKCβII (IC50 = 49, 102, 110, 198, and 185, respectively).{19367,19883} PP242 has been shown to cause the death of certain human and murine leukemia cells more potently than rapamycin and, in vivo, delays leukemia onset and augments the effects of tyrosine kinase inhibitors in suppressing leukemic expansion and extending survival.{18005}
Brand:CaymanSKU:-
The Src family of non-receptor tyrosine kinases regulate cell adhesion, growth, and differentiation through activation of multiple intracellular signaling pathways. Normally inactive, Src kinases are transiently activated during mitosis and constitutively activated by abnormal mutations. Several small molecule inhibitors of this signaling pathway have been developed as a therapeuptic strategy to abate abnormal Src kinase activity. PP3 is an inactive analog of the Src tyrosine kinase inhibitors PP1 (Item No. 14244) and PP2 (Item No. 13198). At concentrations as high as 10 μM, it does not prevent proliferation mediated by a stem cell factor/mast cell growth factor in hematopoietic and cancer cell lines.{22347,22349}
Brand:CaymanSKU:- The Src family of non-receptor tyrosine kinases regulate cell adhesion, growth, and differentiation through activation of multiple intracellular signaling pathways. Normally inactive, Src kinases are transiently activated during mitosis and constitutively activated by abnormal mutations. Several small molecule inhibitors of this signaling pathway have been developed as a therapeuptic strategy to abate abnormal Src kinase activity. PP3 is an inactive analog of the Src tyrosine kinase inhibitors PP1 (Item No. 14244) and PP2 (Item No. 13198). At concentrations as high as 10 μM, it does not prevent proliferation mediated by a stem cell factor/mast cell growth factor in hematopoietic and cancer cell lines.{22347,22349}
Brand:CaymanSKU:- The Src family of non-receptor tyrosine kinases regulate cell adhesion, growth, and differentiation through activation of multiple intracellular signaling pathways. Normally inactive, Src kinases are transiently activated during mitosis and constitutively activated by abnormal mutations. Several small molecule inhibitors of this signaling pathway have been developed as a therapeuptic strategy to abate abnormal Src kinase activity. PP3 is an inactive analog of the Src tyrosine kinase inhibitors PP1 (Item No. 14244) and PP2 (Item No. 13198). At concentrations as high as 10 μM, it does not prevent proliferation mediated by a stem cell factor/mast cell growth factor in hematopoietic and cancer cell lines.{22347,22349}
Brand:CaymanSKU:-
PPA is the product of peroxidase-catalyzed reduction of PPHP. It can be used as a reference standard for HPLC analysis of peroxidase assays.{1054,1073}
Brand:CaymanSKU:75751 - 1 mgAvailable on backorder
PPA is the product of peroxidase-catalyzed reduction of PPHP. It can be used as a reference standard for HPLC analysis of peroxidase assays.{1054,1073}
Brand:CaymanSKU:75751 - 10 mgAvailable on backorder
PPA is the product of peroxidase-catalyzed reduction of PPHP. It can be used as a reference standard for HPLC analysis of peroxidase assays.{1054,1073}
Brand:CaymanSKU:75751 - 5 mgAvailable on backorder
PPA is the product of peroxidase-catalyzed reduction of PPHP. It can be used as a reference standard for HPLC analysis of peroxidase assays.{1054,1073}
Brand:CaymanSKU:75751 - 500 µgAvailable on backorder
Kallikreins are a class of serine proteases that affect the release of vasodepressor peptides or kinins from a plasma substrate. PPACKII is a specific and irreversible inhibitor of glandular and plasma kallikreins.{24966} At micromolar concentrations it has been shown to prevent apolipoprotein proteolysis in dextran sulfate-precipitated human plasma LDL and to inhibit serum atrial natriuretic peptide cleavage.{2805} PPACKII has also been reported to inactivate the amidolytic activity of native human Hageman Factor (Factor XII) at 5.3 μM.{24967}
Brand:CaymanSKU:- Kallikreins are a class of serine proteases that affect the release of vasodepressor peptides or kinins from a plasma substrate. PPACKII is a specific and irreversible inhibitor of glandular and plasma kallikreins.{24966} At micromolar concentrations it has been shown to prevent apolipoprotein proteolysis in dextran sulfate-precipitated human plasma LDL and to inhibit serum atrial natriuretic peptide cleavage.{2805} PPACKII has also been reported to inactivate the amidolytic activity of native human Hageman Factor (Factor XII) at 5.3 μM.{24967}
Brand:CaymanSKU:-